MD Anderson Cancer Center, University of Pennsylvania Medical Center, Yale Medical Center, Harvard University Medical School, Cleveland Clinic
Founders
Lynnet Koh, Michael Lemaire, Alan Lewis
Company Description
TargaZyme is pioneering the next frontier of cancer medicine with the development of therapeutics that harnesses the power of a patient’s own immune system without the toxic chemotherapies, radiation, radical surgery or other toxic cancer drugs that make up today’s standard of care. TargaZyme is currently pre-revenue and in the R&D stage with our two breakthrough approaches: TZ101, a Phase-3 ready product, and TZ102, which is currently being prepared for clinical or human-patient trials.